The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
Quick Facts
What This Study Found
Liraglutide reduced calorie intake but did not improve overall diet quality compared to dietitian-guided caloric restriction. The caloric restriction group made bigger improvements in protein intake and added sugar reduction.
Key Numbers
70 participants (69% female, 83% white, mean BMI 39.5). 2:1:1 randomization. Liraglutide 1.8 mg/day for 14 weeks. Significant differences in protein (p=0.037), carbs (p=0.019), and added sugar (p=0.002) changes across groups.
How They Did This
Secondary analysis of a randomized controlled trial. 24-hour dietary recall pre- and post-intervention. Compared liraglutide, dietitian-guided caloric restriction (-390 kcal/day), and DPP4 inhibitor (100 mg/day).
Why This Research Matters
GLP-1 drugs help people eat less, but they do not necessarily help people eat better. Adding nutrition counseling to GLP-1 treatment may be important for long-term health outcomes beyond weight loss.
What This Study Doesn't Tell Us
Small sample (70 patients). Single 24-hour recall may not capture habitual intake. Short duration (14 weeks). Secondary analysis, not powered for dietary outcomes.
Trust & Context
- Original Title:
- The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
- Published In:
- Diabetes, obesity & metabolism, 27(7), 3725-3735 (2025)
- Authors:
- Richardson, Kelli M, Schembre, Susan M, Jospe, Michelle R, Widmer, Annaliese, Silver, Heidi J
- Database ID:
- RPEP-13262
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13262APA
Richardson, Kelli M; Schembre, Susan M; Jospe, Michelle R; Widmer, Annaliese; Silver, Heidi J. (2025). The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.. Diabetes, obesity & metabolism, 27(7), 3725-3735. https://doi.org/10.1111/dom.16395
MLA
Richardson, Kelli M, et al. "The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.." Diabetes, 2025. https://doi.org/10.1111/dom.16395
RethinkPeptides
RethinkPeptides Research Database. "The influence of the glucagon-like peptide-1 receptor agonis..." RPEP-13262. Retrieved from https://rethinkpeptides.com/research/richardson-2025-the-influence-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.